SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity
Clinical Infectious Diseases | November 2, 2021
Sherman AC, Desjardins M, Cheng CA, Bausk B, Izaguirre N, Zhou G, Krauss J, Tolan N, Walt DR, Soiffer R, Ho VT, Issa NC and Baden LR
Clin Infect Dis. 2021
This study was performed using Simoa Homebrew assay(s).
The severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine–induced humoral response and reactogenicity profile are described in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Findings showed that 75.0% (by Simoa assay) or 80.0% (by Roche assay) of the HSCT cohort had a positive antibody response on series completion, compared with 100% in the healthy cohort.
Share this page